The four board members who voted Arcturus Therapeutics Inc. founder Joseph Payne out of the RNA drug development firm at the end of January have been replaced under a settlement between the executive and the company announced May 29. And now, as of May 31, Payne has been reinstated as president and CEO, four months after he was unexpectedly fired.
Payne, who is Arcturus' largest shareholder with a 13.7% stake in the San Diego-based company, has demanded since the beginning...
Welcome to Scrip
Create an account to read this article
Already a subscriber?